LivaNova (NASDAQ:LIVN) Rating Lowered to Hold at Zacks Research

LivaNova (NASDAQ:LIVN) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on the company. Robert W. Baird cut their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Needham & Company LLC increased their price objective on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Barclays increased their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Mizuho raised their target price on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, Freedom Capital raised LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $83.50.

LivaNova Stock Down 3.3%

LIVN stock opened at $78.21 on Wednesday. The stock has a market cap of $4.31 billion, a PE ratio of 23.14 and a beta of 0.86. The firm’s 50-day simple moving average is $80.56 and its 200 day simple moving average is $71.83. LivaNova has a fifty-two week low of $48.82 and a fifty-two week high of $85.76. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The firm had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. During the same period in the previous year, the business posted $1.05 EPS. LivaNova’s revenue was up 10.8% on a year-over-year basis. As a group, sell-side analysts predict that LivaNova will post 3.77 EPS for the current year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.35% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. boosted its stake in LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming bought a new stake in shares of LivaNova in the 2nd quarter worth $31,000. EverSource Wealth Advisors LLC raised its stake in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares in the last quarter. Quarry LP acquired a new stake in shares of LivaNova in the third quarter valued at $36,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of LivaNova in the second quarter valued at $37,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.